Salamander-Inspired Nanocages Deliver Drugs Deep Into Injured Kidney Cells

When a salamander loses a limb, it grows a new one — and at the heart of that regenerative feat lies a cellular powerhouse that most mammals simply cannot switch back on after injury. Now, a team of researchers in China has borrowed that biological principle to tackle one of modern medicine’s most stubborn problems: acute kidney injury, a condition that strikes an estimated 13 million people each year and kills 1.7 million. In a study published in Materials Today Bio, the group describes a biomimetic nanoplatform, dubbed GIPL, that shuttles a mitochondrial drug deep into the damaged cells of the kidney — and lets doctors watch it arrive in real time.

The inspiration came from the axolotl, Ambystoma mexicanum, whose limbs and organs regenerate throughout its lifespan. Recent single-cell transcriptomic studies have revealed a specialized population of mitochondria-related cells that provide metabolic support during axolotl limb regeneration, and work in regenerating zebrafish hearts has similarly identified mitochondrial restoration as a prerequisite for tissue repair. The lesson the researchers drew is deceptively simple: robust mitochondrial function is indispensable for regeneration. Mammalian kidneys, by contrast, fail to reactivate mitochondrial repair programs after acute insults, leaving injured tubular cells stuck in a downward spiral of energy failure and oxidative damage.

Acute kidney injury is particularly insidious because its clinical diagnosis lags behind the damage. Physicians typically rely on rising serum creatinine and falling urine output — signals that only appear after substantial tubular injury has already occurred, narrowing the window for intervention. Treatment remains largely supportive: fluids, hemodynamic stabilization, and dialysis when necessary. None of these approaches addresses the underlying cellular pathology. At the center of that pathology sit the kidney’s proximal tubular epithelial cells, which depend heavily on mitochondrial oxidative phosphorylation to power their energy-intensive reabsorption work. When ischemia-reperfusion injury or toxic drugs strike, these cells’ mitochondria flood the cell with reactive oxygen species, lose their membrane potential, and deplete ATP, ultimately triggering apoptosis.

To pinpoint a therapeutic strategy, the team first mined transcriptomic data from regenerating axolotl limbs, finding upregulation of genes involved in oxidative stress response, apoptotic signaling, and metabolism. They then compared single-cell RNA sequencing datasets from healthy and injured human kidneys, identifying seven distinct cell populations and confirming that proximal tubule cells in acute kidney injury showed significantly reduced mitochondrial function scores. The convergence was striking: enhanced mitochondrial bioenergetics underlies the axolotl’s regenerative power, while mitochondrial bioenergetic failure drives tubular injury and maladaptive repair in human AKI. Mitochondrial dysfunction, the authors argue, is not merely a downstream casualty of kidney injury but a central driver of disease progression.

Network pharmacology pointed the researchers toward idebenone, a synthetic short-chain benzoquinone analog of coenzyme Q10 already clinically approved for the mitochondrial disease Leber’s hereditary optic neuropathy. Database screening identified 94 overlapping targets between idebenone and AKI, with protein-protein interaction analysis highlighting mTOR as a central hub connecting autophagy regulation, apoptosis, and mitochondrial homeostasis. Molecular docking simulations predicted favorable binding between idebenone and mTOR, with a binding energy of −7.5 kcal/mol, and cell experiments confirmed that free idebenone suppresses phosphorylated mTOR in a dose-dependent manner. The problem was delivery: idebenone is poorly water-soluble and has no inherent kidney specificity, so without a carrier it would never reach the mitochondria of injured tubular cells in useful quantities.

The delivery vehicle the team engineered is a gold-silver nanocage — a hollow, porous bimetallic structure roughly 79 nanometers in diameter once fully assembled. The hollow architecture efficiently encapsulates hydrophobic drugs, while gold’s high X-ray attenuation makes the particles visible on computed tomography. Assembly proceeded stepwise: idebenone was loaded into the nanocages, the surface was cloaked in PEG for stability, and finally a targeting peptide called LTH was conjugated to the exterior. Transmission electron microscopy tracked each stage, and spectroscopy confirmed the additions — a new peak around 280 nanometers corresponding to the tryptophan residue in the LTH peptide, and characteristic amide bands in the infrared spectrum after peptide coupling. High-performance liquid chromatography measured a drug loading content of nearly 20 percent by weight, and residual solvent and metal ion analyses fell far below international impurity limits.

The targeting logic works as a cascade, in two sequential steps. First, the LTH peptide recognizes kidney injury molecule-1, or KIM-1, a transmembrane glycoprotein barely detectable in healthy kidneys but dramatically upregulated on injured proximal tubular cells. This transforms a pathological marker into a homing beacon: only damaged cells display the receptor, so only damaged cells take up the particles. Second, once inside, the released idebenone exploits its inherent mitochondriotropic properties to accumulate at the organelle where it is needed most. In laboratory tests with hydrogen peroxide-injured human tubular epithelial cells, fluorescently labeled GIPL showed markedly enhanced uptake compared with non-targeted formulations, and confocal imaging revealed strong co-localization between the particles and mitochondria, with a Pearson’s correlation coefficient of 0.78.

The functional results in cells were equally striking. GIPL treatment reduced mitochondrial superoxide generation by roughly 75 percent compared with injured untreated cells, restored mitochondrial membrane potential as measured by JC-1 staining, and cut apoptosis rates from about 23 percent to about 8 percent. RNA sequencing of treated cells revealed the mechanism: GIPL suppresses mTOR phosphorylation, which relieves inhibition of autophagy and mitophagy — the cellular housekeeping that clears damaged mitochondria — while simultaneously dialing down pro-apoptotic signaling. Levels of the autophagy marker LC3-II rose, the cargo receptor P62 fell, and pro-apoptotic proteins such as cleaved caspase-3, Bax, and released cytochrome c all declined. The result is a coordinated rescue of mitochondrial homeostasis rather than a single-point intervention.

In mice subjected to renal ischemia-reperfusion injury, the cascade targeting translated into roughly threefold higher renal accumulation of GIPL compared with non-targeted particles, confirmed both by fluorescence imaging and by mass spectrometry quantification of gold content in organs. Because the nanocages are intrinsically CT-visible, the researchers could non-invasively track accumulation in the injured kidneys, with CT values rising linearly with particle concentration. Therapeutically, GIPL significantly reduced histological injury scores, brought serum creatinine and blood urea nitrogen back toward normal levels, lowered renal reactive oxygen species, dampened inflammatory cytokines, and — critically — restored mitochondrial ultrastructure under the electron microscope, preserving cristae integrity where untreated injured kidneys showed matrix swelling and membrane rupture. The particles cleared mainly through the liver and bile into feces, with urine as a secondary route, and comprehensive safety testing in healthy mice showed no organ toxicity, blood count abnormalities, or liver and kidney function changes.

The authors are careful to note the limits of the work: efficacy was demonstrated only in the ischemia-reperfusion model, not in nephrotoxic or sepsis-associated forms of AKI, and all in vivo experiments were performed in mice, with large-animal studies needed before clinical translation. Still, the study represents a rare trifecta in nanomedicine — cell-type-specific targeting, subcellular delivery to the disease-relevant organelle, and integrated diagnostic imaging in a single platform. By translating the axolotl’s mitochondrial secret into a programmable nanocage, the researchers have shown that the line between regenerative biology and human therapeutics may be shorter than anyone expected. For the millions who develop acute kidney injury each year, that could eventually mean treatment that reaches the exact spot where the damage begins — and lets clinicians see it working.

Subject of Research: Biomimetic cascade-targeted nanocages for theranostic treatment of ischemia-reperfusion acute kidney injury via mitochondrial protection

Article Title: Biomimetic nanocages with cascade homing for theranostics of ischemia-reperfusion acute kidney injury

Article References: Xu, Z., Wan, Y., Shang, Y., He, K., Jiang, C., Du, G., Zhao, Y., Hu, Q., Zhang, Y., Zhang, G., & Yan, X. (2026). Biomimetic nanocages with cascade homing for theranostics of ischemia-reperfusion acute kidney injury. Materials Today Bio, 41, Article 103730. https://doi.org/10.1016/j.mtbio.2026.103730

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103730

Keywords: acute kidney injury, nanomedicine, mitochondria, axolotl, gold-silver nanocages, idebenone, KIM-1, mTOR, mitophagy, theranostics, CT imaging, ischemia-reperfusion